CCNA2 and E2F1

Number of citations of the paper that reports this interaction (PubMedID 12501191)
47

Data Source:
HPRD (in vitro)

		CCNA2	E2F1
Description		cyclin A2	E2F transcription factor 1
Image
GO Annotations	Cellular Component	Cyclin-dependent Protein Kinase Holoenzyme Complex Female Pronucleus Male Pronucleus Nucleus Nucleoplasm Cytoplasm Cytosol Cyclin A2-CDK2 Complex	Nuclear Chromatin Nucleus Nucleoplasm Mitochondrion Centrosome Protein-containing Complex Rb-E2F Complex RNA Polymerase II Transcription Factor Complex
	Molecular Function	Protein Kinase Activity Protein Binding Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Protein Kinase Binding Protein Domain Specific Binding Cyclin-dependent Protein Kinase Activity	DNA-binding Transcription Factor Activity, RNA Polymerase II-specific Proximal Promoter Sequence-specific DNA Binding Bacterial-type RNA Polymerase Transcriptional Activator Activity, Sequence-specific DNA Binding DNA Binding DNA-binding Transcription Factor Activity Protein Binding Transcription Factor Binding Protein Kinase Binding Sequence-specific DNA Binding Protein Dimerization Activity
	Biological Process	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G2/M Transition Of Mitotic Cell Cycle Regulation Of DNA Replication Ras Protein Signal Transduction Viral Process Histone Phosphorylation Protein Deubiquitination Animal Organ Regeneration Response To Glucagon Cellular Response To Platelet-derived Growth Factor Stimulus Cellular Response To Leptin Stimulus Mitotic Cell Cycle Phase Transition Cell Cycle G1/S Phase Transition Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fibroblast Proliferation Cell Division Cellular Response To Cocaine Cellular Response To Luteinizing Hormone Stimulus Cellular Response To Estradiol Stimulus Cellular Response To Hypoxia Cellular Response To Nitric Oxide Cochlea Development Cellular Response To Insulin-like Growth Factor Stimulus	DNA Damage Checkpoint Regulation Of Transcription Involved In G1/S Transition Of Mitotic Cell Cycle Negative Regulation Of Transcription By RNA Polymerase II Transcription, DNA-templated Regulation Of Transcription, DNA-templated DNA Damage Response, Signal Transduction By P53 Class Mediator Resulting In Cell Cycle Arrest Spermatogenesis Intrinsic Apoptotic Signaling Pathway In Response To DNA Damage Positive Regulation Of Gene Expression Viral Process Forebrain Development Positive Regulation Of Apoptotic Process Anoikis Negative Regulation Of DNA Binding Negative Regulation Of Fat Cell Differentiation Negative Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription By RNA Polymerase II Positive Regulation Of Fibroblast Proliferation MRNA Stabilization Regulation Of Cell Cycle Positive Regulation Of Glial Cell Proliferation Negative Regulation Of G0 To G1 Transition Negative Regulation Of Fat Cell Proliferation Cellular Response To Fatty Acid Cellular Response To Hypoxia Cellular Response To Xenobiotic Stimulus Negative Regulation Of Transcription Involved In G1/S Transition Of Mitotic Cell Cycle Intrinsic Apoptotic Signaling Pathway By P53 Class Mediator Positive Regulation Of Protein Insertion Into Mitochondrial Membrane Involved In Apoptotic Signaling Pathway Lens Fiber Cell Apoptotic Process Cellular Response To Nerve Growth Factor Stimulus Regulation Of G1/S Transition Of Mitotic Cell Cycle
Pathways		Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Ub-specific processing proteases Processing of DNA double-strand break ends TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation G2 Phase Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry	Activation of NOXA and translocation to mitochondria Inhibition of replication initiation of damaged DNA by RB1/E2F1 Transcription of E2F targets under negative control by DREAM complex Transcription of E2F targets under negative control by DREAM complex Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Oncogene Induced Senescence TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest CDC6 association with the ORC:origin complex G2 Phase Cyclin E associated events during G1/S transition G1/S-Specific Transcription G1/S-Specific Transcription Cyclin D associated events in G1 Cyclin A:Cdk2-associated events at S phase entry Transcriptional Regulation by E2F6 Transcriptional regulation of granulopoiesis Transcriptional regulation of granulopoiesis
Drugs		4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine 6-O-Cyclohexylmethyl Guanine [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol
Diseases
GWAS			Heel bone mineral density ( 30598549) Height ( 31562340)
Interacting Genes		48 interacting genes: ARID4A BRCA1 BRCA2 BTG1 BUB1B CALM1 CDC20 CDC25C CDC6 CDK1 CDK2 CDK3 CDKN1A CDKN1B CDT1 DTNBP1 E2F1 E2F3 FANCC FEN1 H1-1 H1-5 HERC5 HIRA ITGB3BP KAT2B MAD2L1 MAGEA11 MYBL2 NFYA PGR POLA1 PRC1 PSMD4 PTMA RAD23A RB1 RBL1 RBL2 RPA1 SKP1 SKP2 SP1 TAF1 TP53 TRAF3IP1 UBTF USP37	83 interacting genes: ARID3A ATAD2 ATM ATR BIN1 BIRC2 BRCA1 BRD2 BRMS1 BTRC CCNA1 CCNA2 CDK1 CDK2 CDK3 CDK7 CDKN2A CEBPE CHEK2 CREBBP CTDP1 CUL1 CUL2 DDB2 DIABLO E2F6 EP300 ERCC3 FHL2 GSK3B GTF2H1 HCFC1 IGF1 KAT5 KDM1A MDM2 MDM4 MGA MNAT1 MPHOSPH10 MTA1 MYBL2 NCOA3 NCOA6 NCOR2 NDN NFKB1 NPDC1 NRIP1 NSMCE3 PARP1 PHB PKIB PRDM2 PURA RARA RB1 RBL1 RNF126 RNF144A SERTAD2 SETD7 SIRT1 SKP2 SP1 SP2 SP3 SP4 SPIB STAT1 STOML1 TBP TEAD3 TFDP1 TFDP2 TOPBP1 TP53 TP53BP1 TRRAP UBE3A UCHL5 VHL YWHAQ
Entrez ID		890	1869
HPRD ID		00453	01806
Ensembl ID		ENSG00000145386	ENSG00000101412
Uniprot IDs		P20248	Q01094 Q9BSD8
PDB IDs		1E9H 1FIN 1FVV 1GY3 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1JST 1JSU 1OGU 1OI9 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P5E 1PKD 1QMZ 1URC 1VYW 2BKZ 2BPM 2C4G 2C5N 2C5O 2C5V 2C5X 2C6T 2CCH 2CCI 2CJM 2I40 2IW6 2IW8 2IW9 2UUE 2UZB 2UZD 2UZE 2UZL 2V22 2WEV 2WFY 2WHB 2WIH 2WIP 2WMA 2WMB 2WPA 2WXV 2X1N 3EID 3EJ1 3EOC 3F5X 4BCK 4BCM 4BCN 4BCP 4CFM 4CFN 4CFU 4CFV 4CFW 4CFX 4EOI 4EOJ 4EOK 4EOL 4EOM 4EON 4EOO 4EOP 4EOQ 4EOR 4EOS 4FX3 5CYI 5IF1 5LMK 5NEV 6ATH 6GVA 6P3W 6Q6G 6Q6H	1H24 1O9K 2AZE 5M9N 5M9O 6G0P
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?